AXL and non-small cell lung carcinoma: Clinically we found that, in a large cohort of PDAC and NSCLC clinical specimens, the integrated high expression levels of ENAH/AXL/GAS6 positively correlate with poor prognosis (Fig 7A and B; Appendix Fig S12) providing a novel predictive signature in PDAC and NSCLC progression.